

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Developing better drugs for pulmonary... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-2149/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-2149" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns" />
    
            <meta name="og:title" content="F1000Research Article: Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.">
            <meta name="og:description" content="Read the latest article version by Marc A Judson, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="22762">
            <meta name="article-id" content="20696">
            <meta name="dc.title" content="Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns">
            <meta name="dc.description" content="Pulmonary sarcoidosis involves the deposition of granulomas within the lung. These granulomas may affect lung function and lead to pulmonary symptoms, pulmonary dysfunction, functional impairment, and worsening of quality of life. Corticosteroids are generally highly effective in resolving the granulomatous inflammation of sarcoidosis. However, despite the effectiveness of corticosteroids, many corticosteroid-responsive patients continue to experience significant problems because of the development of fibrosis from previously active or active smoldering granulomatous inflammation, inflammatory effects from sarcoidosis unrelated to granuloma deposition in lung tissue (parasarcoidosis syndromes), and the development of significant corticosteroid-related side effects. For these reasons, the decision to treat pulmonary sarcoidosis and endpoints to measure meaningful outcomes may extend beyond considerations of pulmonary granulomatous inflammation alone. In this article, we propose a conceptual framework to describe the mechanisms by which pulmonary sarcoidosis significantly impacts patients. This conceptual framework suggests that indications for the treatment of pulmonary sarcoidosis and endpoints to assess treatment depend on the specific mechanisms that are causing functional or quality-of-life impairment (or both) in patients with pulmonary sarcoidosis. We believe that these concepts are important to clinicians treating pulmonary sarcoidosis and to clinical researchers designing pulmonary sarcoidosis trials.">
            <meta name="dc.subject" content="Sarcoidosis, treatment, endpoints, corticosteroids, fibrosis, quality of life">
            <meta name="dc.creator" content="Judson, Marc A">
            <meta name="dc.date" content="2020/12/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.20696.1">
            <meta name="dc.source" content="F1000Research 2019 8:2149">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Sarcoidosis">
            <meta name="prism.keyword" content="treatment">
            <meta name="prism.keyword" content="endpoints">
            <meta name="prism.keyword" content="corticosteroids">
            <meta name="prism.keyword" content="fibrosis">
            <meta name="prism.keyword" content="quality of life">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/12/30">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="2149">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.20696.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-2149">
            <meta name="citation_title" content="Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns">
            <meta name="citation_abstract" content="Pulmonary sarcoidosis involves the deposition of granulomas within the lung. These granulomas may affect lung function and lead to pulmonary symptoms, pulmonary dysfunction, functional impairment, and worsening of quality of life. Corticosteroids are generally highly effective in resolving the granulomatous inflammation of sarcoidosis. However, despite the effectiveness of corticosteroids, many corticosteroid-responsive patients continue to experience significant problems because of the development of fibrosis from previously active or active smoldering granulomatous inflammation, inflammatory effects from sarcoidosis unrelated to granuloma deposition in lung tissue (parasarcoidosis syndromes), and the development of significant corticosteroid-related side effects. For these reasons, the decision to treat pulmonary sarcoidosis and endpoints to measure meaningful outcomes may extend beyond considerations of pulmonary granulomatous inflammation alone. In this article, we propose a conceptual framework to describe the mechanisms by which pulmonary sarcoidosis significantly impacts patients. This conceptual framework suggests that indications for the treatment of pulmonary sarcoidosis and endpoints to assess treatment depend on the specific mechanisms that are causing functional or quality-of-life impairment (or both) in patients with pulmonary sarcoidosis. We believe that these concepts are important to clinicians treating pulmonary sarcoidosis and to clinical researchers designing pulmonary sarcoidosis trials.">
            <meta name="citation_description" content="Pulmonary sarcoidosis involves the deposition of granulomas within the lung. These granulomas may affect lung function and lead to pulmonary symptoms, pulmonary dysfunction, functional impairment, and worsening of quality of life. Corticosteroids are generally highly effective in resolving the granulomatous inflammation of sarcoidosis. However, despite the effectiveness of corticosteroids, many corticosteroid-responsive patients continue to experience significant problems because of the development of fibrosis from previously active or active smoldering granulomatous inflammation, inflammatory effects from sarcoidosis unrelated to granuloma deposition in lung tissue (parasarcoidosis syndromes), and the development of significant corticosteroid-related side effects. For these reasons, the decision to treat pulmonary sarcoidosis and endpoints to measure meaningful outcomes may extend beyond considerations of pulmonary granulomatous inflammation alone. In this article, we propose a conceptual framework to describe the mechanisms by which pulmonary sarcoidosis significantly impacts patients. This conceptual framework suggests that indications for the treatment of pulmonary sarcoidosis and endpoints to assess treatment depend on the specific mechanisms that are causing functional or quality-of-life impairment (or both) in patients with pulmonary sarcoidosis. We believe that these concepts are important to clinicians treating pulmonary sarcoidosis and to clinical researchers designing pulmonary sarcoidosis trials.">
            <meta name="citation_keywords" content="Sarcoidosis, treatment, endpoints, corticosteroids, fibrosis, quality of life">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Marc A Judson">
            <meta name="citation_author_institution" content="Division of Pulmonary and Critical Care Medicine, Department of Medicine, Albany Medical College, Albany, NY, USA">
            <meta name="citation_publication_date" content="2020/12/30">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="2149">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.20696.1">
            <meta name="citation_firstpage" content="2149">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-2149/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-2149.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=22762 /> <input type=hidden id=articleId name=articleId value=20696 /> <input type=hidden id=xmlUrl value="/articles/8-2149/v1/xml"/> <input type=hidden id=xmlFileName value="-8-2149-v1.xml"> <input type=hidden id=article_uuid value=69307855-6eae-4a15-9515-65fd8bdefcdc /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.20696.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.20696.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-2149"
  },
  "headline": "Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to...",
  "datePublished": "2019-12-30T12:16:36",
  "dateModified": "2019-12-30T12:16:36",
  "author": [
    {
      "@type": "Person",
      "name": "Marc A Judson"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Pulmonary sarcoidosis involves the deposition of granulomas within the lung. These granulomas may affect lung function and lead to pulmonary symptoms, pulmonary dysfunction, functional impairment, and worsening of quality of life. Corticosteroids are generally highly effective in resolving the granulomatous inflammation of sarcoidosis. However, despite the effectiveness of corticosteroids, many corticosteroid-responsive patients continue to experience significant problems because of the development of fibrosis from previously active or active smoldering granulomatous inflammation, inflammatory effects from sarcoidosis unrelated to granuloma deposition in lung tissue (parasarcoidosis syndromes), and the development of significant corticosteroid-related side effects. For these reasons, the decision to treat pulmonary sarcoidosis and endpoints to measure meaningful outcomes may extend beyond considerations of pulmonary granulomatous inflammation alone. In this article, we propose a conceptual framework to describe the mechanisms by which pulmonary sarcoidosis significantly impacts patients. This conceptual framework suggests that indications for the treatment of pulmonary sarcoidosis and endpoints to assess treatment depend on the specific mechanisms that are causing functional or quality-of-life impairment (or both) in patients with pulmonary sarcoidosis. We believe that these concepts are important to clinicians treating pulmonary sarcoidosis and to clinical researchers designing pulmonary sarcoidosis trials."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-2149",
            "name": "Developing better drugs for pulmonary sarcoidosis: determining indications..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Developing better drugs for pulmonary sarcoidosis: determining indications... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=22762 data-id=20696 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20696.1" data-recommended="" data-doi="10.12688/f1000research.20696.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-2149/v1/pdf?article_uuid=69307855-6eae-4a15-9515-65fd8bdefcdc" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-20696-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-20696-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-20696-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Judson MA. Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2149 (<a class=new-orange href="https://doi.org/10.12688/f1000research.20696.1" target=_blank>https://doi.org/10.12688/f1000research.20696.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-20696-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=20696 id=track-article-signin-20696 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20696?target=/articles/8-2149">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22762 /> <input name=articleId type=hidden value=20696 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:judsonm@amc.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Marc A Judson</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:judsonm@amc.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Marc A Judson</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Dec 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.20696.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Pulmonary and Critical Care Medicine, Department of Medicine, Albany Medical College, Albany, NY, USA<br/> <p> <div class=margin-bottom> Marc A Judson <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61452-57713></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61453-57715></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61454-57714></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Pulmonary sarcoidosis involves the deposition of granulomas within the lung. These granulomas may affect lung function and lead to pulmonary symptoms, pulmonary dysfunction, functional impairment, and worsening of quality of life. Corticosteroids are generally highly effective in resolving the granulomatous inflammation of sarcoidosis. However, despite the effectiveness of corticosteroids, many corticosteroid-responsive patients continue to experience significant problems because of the development of fibrosis from previously active or active smoldering granulomatous inflammation, inflammatory effects from sarcoidosis unrelated to granuloma deposition in lung tissue (parasarcoidosis syndromes), and the development of significant corticosteroid-related side effects. For these reasons, the decision to treat pulmonary sarcoidosis and endpoints to measure meaningful outcomes may extend beyond considerations of pulmonary granulomatous inflammation alone. In this article, we propose a conceptual framework to describe the mechanisms by which pulmonary sarcoidosis significantly impacts patients. This conceptual framework suggests that indications for the treatment of pulmonary sarcoidosis and endpoints to assess treatment depend on the specific mechanisms that are causing functional or quality-of-life impairment (or both) in patients with pulmonary sarcoidosis. We believe that these concepts are important to clinicians treating pulmonary sarcoidosis and to clinical researchers designing pulmonary sarcoidosis trials. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Sarcoidosis, treatment, endpoints, corticosteroids, fibrosis, quality of life </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Marc A Judson (<a href="mailto:judsonm@amc.edu">judsonm@amc.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Marc A Judson </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The author has received grant support for his institution from Mallinckrodt, Novartis, and aTyr. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Judson MA. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Judson MA. Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2149 (<a href="https://doi.org/10.12688/f1000research.20696.1" target=_blank>https://doi.org/10.12688/f1000research.20696.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Dec 2019, <b>8</b>(F1000 Faculty Rev):2149 (<a href="https://doi.org/10.12688/f1000research.20696.1" target=_blank>https://doi.org/10.12688/f1000research.20696.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Dec 2019, <b>8</b>(F1000 Faculty Rev):2149 (<a href="https://doi.org/10.12688/f1000research.20696.1" target=_blank>https://doi.org/10.12688/f1000research.20696.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d6690e127>Introduction</h2><p class="" id=d6690e130>Sarcoidosis is a multisystem granulomatous disease of unknown cause. Granulomas consist of conglomerations of inflammatory cells, predominantly lymphocytes and macrophages. In sarcoidosis, these granulomas may deposit in any organ but most commonly develop within the lung, where they are found in more than 90% of sarcoidosis cases<sup><a href="#ref-1">1</a></sup>. The decision to treat pulmonary sarcoidosis is complex because (a) the disease may cause neither symptoms nor permanent organ damage<sup><a href="#ref-2">2</a></sup>; (b) a small percentage of cases, maybe 10 to 20%, are progressive or cause fibrosis (that may result in permanent lung dysfunction, significant morbidity, and even mortality) or both<sup><a href="#ref-3">3</a></sup>; (c) there are no reliable biomarkers to predict whether the natural course of pulmonary sarcoidosis will be benign or lead to severe impairment<sup><a href="#ref-4">4</a></sup>; and (d) treatment of pulmonary sarcoidosis with corticosteroids and other therapies is associated with significant toxicity<sup><a href="#ref-5">5</a></sup>. These issues force clinicians, clinical researchers, and pharma to carefully select appropriate pulmonary sarcoidosis patients who have the potential to receive impactful benefits from interventions and to select the appropriate methods to assess therapeutic responses. Clinical trial design for pulmonary sarcoidosis has been problematic, and major trials have been criticized as not adequately accounting for the natural history of the disease in order to determine the benefits of study drugs<sup><a href="#ref-6">6</a></sup>. This article will explore the indications for treatment of pulmonary sarcoidosis and methods to assess the effects of therapy. This exercise will involve the construction of a proposed conceptual framework outlining how pulmonary sarcoidosis leads to outcomes that are clinically impactful to patients or clinicians or both. This conceptual framework will suggest that patients in pulmonary sarcoidosis trials require partitioning into disease profiles that each require distinct clinical endpoints to optimally assess the effects of therapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6690e161>Determining treatment indications on the basis of Wells’s law</h2><div class=section><a name=d6690e164 class=n-a></a><h3 class=section-title>Wells’s law</h3><p class="" id=d6690e169>Because sarcoidosis may affect any organ in the body and its severity is highly variable, it is problematic to define specific criteria for treatment. Most sarcoidosis clinicians agree with Athol Wells’s distillation of the treatment indications for sarcoidosis to just two: situations of danger and significant quality of life (QOL) impairment (“Wells’s law”)<sup><a href="#ref-7">7</a></sup>.</p></div><div class=section><a name=d6690e177 class=n-a></a><h3 class=section-title>Situations of danger from pulmonary sarcoidosis</h3><p class="" id=d6690e182>Sarcoidosis is a systemic disease, and situations of danger are not confined to the lung. Cardiac sarcoidosis may cause sudden death, eye involvement may result in blindness, and neurosarcoidosis may result in coma and permanent neurologic impairment. In the case of pulmonary sarcoidosis, situations of danger develop in a minority of patients and are listed in <a href="#T1">Table 1</a>. Dangerous situations from pulmonary sarcoidosis are confined almost exclusively to those who develop fibrocystic disease, which constitutes 10 to 20% of these patients<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Interestingly, the treatment of most of these dangerous situations involves therapy other than anti-granulomatous therapy, although most clinicians and sarcoidosis drug trials focus on obliterating the sarcoid granuloma.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Situations of danger from pulmonary sarcoidosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6690e206 class=n-a></a><thead><a name=d6690e208 class=n-a></a><tr><a name=d6690e210 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e212 class=n-a></a>Condition</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e215 class=n-a></a>Relationship<br class=br>to fibrosis</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e220 class=n-a></a>Mechanism</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e223 class=n-a></a>Treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e226 class=n-a></a>Percentage of patients<br class=br>with pulmonary<br class=br>sarcoidosis</th></tr></thead><tbody><a name=d6690e235 class=n-a></a><tr><a name=d6690e237 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e239 class=n-a></a>Fibrocystic sarcoidosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e242 class=n-a></a>Very strong</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e245 class=n-a></a>The fibrosis is the result of<br class=br>granulomatous inflammation<br class=br>in a subset of patients with<br class=br>sarcoidosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e254 class=n-a></a>No known direct treatment. Anti-<br class=br>granulomatous therapy may be<br class=br>beneficial in preventing further<br class=br>development of fibrosis.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e263 class=n-a></a>10–20%</td></tr><tr><a name=d6690e267 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e269 class=n-a></a>Sarcoidosis-associated<br class=br>pulmonary hypertension</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e274 class=n-a></a>Strong</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e277 class=n-a></a>Predominantly from fibrotic<br class=br>distortion of the pulmonary<br class=br>vasculature. Other mechanisms<br class=br>may predominate in a minority of<br class=br>patients</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e288 class=n-a></a>Pulmonary vasodilators</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e291 class=n-a></a>5%; most are a subset of<br class=br>patients with fibrocystic<br class=br>sarcoidosis </td></tr><tr><a name=d6690e299 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e301 class=n-a></a>Bronchiectasis, severe<br class=br>airway distortion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e306 class=n-a></a>Strong</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e309 class=n-a></a>Fibrotic distortion of airways</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e312 class=n-a></a>Enhance mucociliary clearance,<br class=br>intermittent appropriate<br class=br>antibiotics, possibly roflumilast</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e319 class=n-a></a>5–10%; most are a<br class=br>subset of patients with<br class=br>fibrocystic sarcoidosis </td></tr><tr><a name=d6690e327 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e329 class=n-a></a>Mycetoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e332 class=n-a></a>Very strong</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e335 class=n-a></a>Colonization of fungus in<br class=br>devitalized, fibrotic lung</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e340 class=n-a></a>Surgical excision, anti-fungal<br class=br>agents given systemically or<br class=br>injected into mycetoma cavities</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e347 class=n-a></a>1%; most are a subset of<br class=br>patients with fibrocystic<br class=br>sarcoidosis</td></tr></tbody></table></div><p class="" id=d6690e358>The immunopathogenesis of fibrosis in sarcoidosis is not well understood. It is not known whether the fibrosis is triggered by profibrotic inflammatory events, by an inherent predisposition toward fibrosis in a subset of patients, or by an exaggerated wound-healing response to uncontrolled, chronic inflammation<sup><a href="#ref-10">10</a></sup>. Mechanisms proposed to be involved in the development of sarcoidosis-associated fibrosis include alveolar macrophage-induced fibrosis<sup><a href="#ref-11">11</a></sup>, transition from a T helper 1 to T helper 2 signature<sup><a href="#ref-12">12</a></sup>, transforming growth factor-beta<sup><a href="#ref-13">13</a></sup>, upregulation of profibrotic genes that may “transmit” signals for fibrosis through the blood compartment<sup><a href="#ref-14">14</a></sup>, and M2 polarization of alveolar macrophages<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d6690e386>It is conjectured that the fibrosis in pulmonary sarcoidosis results from the granulomatous inflammation. This conjecture is supported histologically where the majority of the fibrosis from sarcoidosis develops within or around the granuloma, resulting in a “hyalinized granuloma”<sup><a href="#ref-16">16</a></sup>. This conjecture is further supported anatomically through chest imaging studies<sup><a href="#ref-17">17</a></sup> (<a href="#f1">Figure 1</a>) as well as analyses of explanted end-stage fibrotic lungs of pulmonary sarcoidosis patients undergoing lung transplantation demonstrating that fibrosis is distributed in a lymphangitic pattern, similar to the usual location of pulmonary granulomas<sup><a href="#ref-16">16</a>,<a href="#ref-18">18</a></sup>. Finally, this conjecture is also supported by biomarkers of granulomatous inflammation in that a report of <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography demonstrated significant pulmonary FDG uptake in 22 (85%) of 26 patients with fibrotic pulmonary sarcoidosis<sup><a href="#ref-19">19</a></sup>. These data suggest that the granulomatous inflammation of sarcoidosis and the development of fibrosis often go hand in hand<sup><a href="#ref-20">20</a></sup>. The amount of fibrosis that develops is variable, from negligent to copious amounts. As previously mentioned, a significant fibrotic response from the granulomatous inflammation of sarcoidosis occurs in, at most, only 20% of cases<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Herein lies a key dilemma in preventing the granulomatous-induced fibrosis of sarcoidosis: since there is no available biomarker to predict which 10 to 20% of patients with pulmonary sarcoidosis will develop significant fibrosis, does the clinician (a) treat all pulmonary sarcoidosis with anti-granulomatous therapy that will prevent the development of fibrosis in 10 to 20% but subject 80% to 90% to potential drug toxicities from corticosteroids and other medications or (b) withhold anti-granulomatous therapy that will result in serious complications in the 10 to 20% who develop fibrosis? Clearly, a reliable biomarker that can accurately predict the development of significant pulmonary fibrosis from sarcoidosis is an unmet need. Effective anti-fibrotic therapy would also be very useful for this form of sarcoidosis, although none is available at present.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure1.gif"><img alt="733a038f-6b2e-4d95-ae42-3f58fab3909a_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure1.gif"></a><div class=caption><h3>Figure 1. Chest computed tomography image of a patient with fibrotic pulmonary sarcoidosis.</h3><p id=d6690e440>Note how the fibrosis is concentrated centrally along the bronchovascular bundles. This is the same location where the granulomas from pulmonary sarcoidosis tend to deposit. This location of fibrosis provides anatomic evidence that the fibrosis in sarcoidosis is a by-product of the granulomatous inflammation of the disease. We confirm that we have obtained permission to use this image from the patient included in this presentation.</p></div></div></div><div class=section><a name=d6690e448 class=n-a></a><h3 class=section-title>Sarcoidosis-related impairment of quality of life</h3><p class="" id=d6690e453>Because the dangerous situations associated with pulmonary sarcoidosis are not common, the more common of the two indications suggested by Wells’s law to treat pulmonary sarcoidosis is sarcoidosis-induced impairment of QOL. A survey of 1842 European patients with sarcoidosis found that QOL and functionality were judged as the most important disease outcomes<sup><a href="#ref-21">21</a></sup>. One could argue that sarcoidosis therapy is used primarily to improve physiology or organ function impaired by granulomatous inflammation or to decrease the granuloma burden , but a critical examination of this issue suggests that this is not the case<sup><a href="#ref-22">22</a></sup>. Sarcoidosis-induced granulomatous inflammation may not cause a significant physiologic derangement or result in a significant impairment of QOL<sup><a href="#ref-23">23</a></sup>. A common clinical situation where this is the case is with asymptomatic bilateral hilar lymphadenopathy<sup><a href="#ref-24">24</a></sup>. Even when the granulomatous inflammation of pulmonary sarcoidosis results in physiologic abnormalities, they are often minor<sup><a href="#ref-8">8</a>,<a href="#ref-23">23</a>,<a href="#ref-25">25</a></sup> and do not invariably lead to appreciable symptoms<sup><a href="#ref-23">23</a>,<a href="#ref-25">25</a></sup>. In addition, the correlation between pulmonary dysfunction and pulmonary symptoms is poor in pulmonary sarcoidosis<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>. Therefore, the presence of granulomatous inflammation or mild physiologic derangements from pulmonary sarcoidosis does not mandate anti-sarcoidosis therapy unless the patient’s QOL is significantly impaired or significant organ dysfunction occurs<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d6690e501>QOL assessment in pulmonary sarcoidosis is also significantly impacted by the potential toxicity of therapy, particularly corticosteroids. Corticosteroids are the drug of choice for the treatment of pulmonary sarcoidosis<sup><a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup>. In most instances, they work quickly and reliably. However, they are associated with a number of potential side effects that may impair QOL. These include weight gain, mood swings/psychological disturbances, diabetes, osteoporosis, hypertension, glaucoma, cataracts, edema, acne, increased skin and vascular fragility, and increased risk of infection. Corticosteroid therapy has been clearly linked to the development of significant toxicities in patients with sarcoidosis<sup><a href="#ref-30">30</a></sup>. If the clinician focuses primarily on reducing the granuloma burden or improving physiology, a medication-induced impairment of QOL may be undetected such that the clinician assesses the patient as improved while the patient feels worse off. This scenario may be relatively common, as it has been shown that those receiving corticosteroids at three major university sarcoidosis clinics in the US had statistically and clinically significant reductions in health-related QOL (HRQOL) compared with sarcoidosis patients not receiving corticosteroids<sup><a href="#ref-27">27</a></sup>, and those receiving more than 500 mg or prednisone equivalent per year had a statistically and clinically worse HRQOL than those on a lower total yearly dose<sup><a href="#ref-31">31</a></sup>.</p><p class="" id=d6690e523>The assessment of QOL in pulmonary sarcoidosis is problematic. HRQOL refers to the extent that the physical, social, mental/emotional, cognitive, or spiritual domains (or a combination of these) are affected by a medical condition or its treatment<sup><a href="#ref-32">32</a></sup>. The HRQOL status of a patient may be assessed informally through unstructured historical questioning. Such an assessment may be thorough and used to make treatment decisions, but in the reality of the current era of patient care where time is compressed, such a detailed evaluation rarely takes place<sup><a href="#ref-22">22</a></sup>. For this reason, many have advocated that the assessment of HRQOL in patients with sarcoidosis be assessed by patient-reported outcome measures (PROs), which are patient-administered reports of how they function or feel about their health condition and the effects of therapy<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. HRQOL PROs provide a quantitative assessment of QOL and functional status in order to assess potential therapeutic effects. In addition, HRQOL PROs may be performed outside of patient clinic visit time and even serially between visits to assess the effects of therapy. However, there are several limitations of using HRQOL PROs on which to base pulmonary sarcoidosis treatment decisions. First, although some sarcoidosis disease–specific PROs have been developed and validated<sup><a href="#ref-35">35</a>–<a href="#ref-37">37</a></sup>, most HRQOL PROs used in patients with sarcoidosis are derived from other disease cohorts. However, an HRQOL PRO derived from non-sarcoidosis cohorts may be used in sarcoidosis provided that there is no plausible rationale that patients with sarcoidosis would assess the trait being measured in a different way than the cohort in which the PRO was validated<sup><a href="#ref-23">23</a></sup>. Second, although PROs can reliably assess HRQOL in large clinical cohorts, most PROs have inadequate resolution to be useful in individual patients. PROs developed with modern methodology, such as item response theory (IRT), may have adequate resolution to accurately assess HRQOL in individuals<sup><a href="#ref-38">38</a>–<a href="#ref-40">40</a></sup>. Finally, QOL and HRQOL are not synonymous, as many high-priority QOL issues do not pertain to a medical condition or its treatment. It is often problematic to distinguish HRQOL issues from non-health-related QOL issues using HRQOL PROs. Because of these concerns, the role of HRQOL PROs in determining treatment decisions for individual patients with pulmonary sarcoidosis has not been standardized. There is uniform agreement that the clinician should not make treatment decisions in isolation without some insight into the patient’s HRQOL status, preferences, goals, and wishes.</p><p class="" id=d6690e560>Sarcoidosis may also cause symptoms or organ dysfunction that is not related to tissue deposition of granulomas or the development of fibrosis. These entities are collectively known as parasarcoidosis syndromes<sup><a href="#ref-41">41</a></sup>, and they may be responsible for significant QOL and functional impairment. Examples of parasarcoidosis syndromes are erythema nodosum<sup><a href="#ref-42">42</a></sup>, small fiber neuropathy<sup><a href="#ref-43">43</a></sup>, fatigue syndromes<sup><a href="#ref-44">44</a></sup>, pain syndromes<sup><a href="#ref-45">45</a></sup>, cognitive decline<sup><a href="#ref-46">46</a></sup>, and vitamin D dysregulation<sup><a href="#ref-47">47</a></sup>. It has been postulated that these syndromes result from systemic release of mediators associated with the granulomatous inflammation of sarcoidosis<sup><a href="#ref-43">43</a>,<a href="#ref-48">48</a></sup>. Although these parasarcoidosis syndromes may not result in appreciable pulmonary symptoms, they may be the result of the granulomatous inflammation from pulmonary sarcoidosis. Parasarcoidosis syndromes may respond to anti-granulomatous therapy<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>, although the decision to use such therapy must weigh the benefits versus the side effects of treatment in relation to the impact of the parasarcoidosis syndrome<sup><a href="#ref-22">22</a></sup>. However, the etiology of parasarcoidosis syndromes is probably more complex than simply a result of granulomatous inflammation, as there may be several non-granulomatous contributions to some of these disorders, such as pain, fatigue, and cognitive impairment syndromes related to the psychological impact of the presence of a chronic disease or decreased function/mobility or both<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>.</p></div><div class=section><a name=d6690e618 class=n-a></a><h3 class=section-title>Conceptual framework of how pulmonary sarcoidosis impacts patients</h3><p class="" id=d6690e623>We have proposed a conceptual framework of how pulmonary sarcoidosis impacts patients through the relationships of granulomatous inflammation, physiologic impairment, fibrosis, parasarcoidosis syndromes and the impact of anti-sarcoidosis therapy (<a href="#f2">Figure 2</a>). This conceptual framework will serve as the blueprint for the selection of the appropriate patients with pulmonary sarcoidosis for therapy and the assessment of such therapy that will be outlined below. Based on this conceptual framework, the treatment of pulmonary sarcoidosis can be directed against three different aspects of the disease: anti-granulomatous therapy for acute untreated disease, anti-granulomatous therapy for chronically treated disease, and therapy for fibrotic sarcoidosis.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure2.gif"><img alt="733a038f-6b2e-4d95-ae42-3f58fab3909a_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure2.gif"></a><div class=caption><h3>Figure 2. A conceptual framework of how pulmonary sarcoidosis impacts patients.</h3><p id=d6690e639>The framework outlines the relationships of granulomatous inflammation, physiologic impairment, fibrosis, parasarcoidosis syndromes, and the impact of anti-sarcoidosis therapy. Assessments refer to methods to assess the processes described within the boxes. Black arrows show the potential clinical progression of pulmonary sarcoidosis directly related to pulmonary deposition of sarcoidosis granulomas. This process is potentially reversible. Red arrows show the potential clinical progression of pulmonary sarcoidosis from pulmonary fibrosis. This process is irreversible. Green arrows show the potential clinical progression of pulmonary sarcoidosis from the development of parasarcoidosis syndromes. These processes may be reversible. Blue arrows show the effects of anti-granulomatous therapy that may reduce granulomatous inflammation (−) and thereby improve health-related quality of life (+). However, the toxicity of anti-granulomatous therapy, particularly corticosteroids, may worsen health-related quality of life (−). 6MWT, 6-minute walk test; BAL, bronchoalveolar lavage; CT, computed tomography; CXR, chest x-ray; DLCO, diffusing capacity of carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HRQL, health-related quality of life; HRQoL, health-related quality of life; PET, positron emission tomography.</p></div></div></div><div class=section><a name=d6690e648 class=n-a></a><h3 class=section-title>What the conceptual framework does not measure</h3><p class="" id=d6690e653>This conceptual framework is directed at immunologic and physiologic factors of pulmonary sarcoidosis that impact patient health. It reflects relevant issues concerning the evaluation of these drugs in clinical pulmonary sarcoidosis trials, including the establishment of study entry criteria and clinically relevant endpoints. However, issues concerning the management of patients with pulmonary sarcoidosis extend beyond these immunologic and physiologic factors. For example, psychosocial and socioeconomic concerns are important considerations of therapy. Such concerns include the cost of care, including medication costs, access to care, social support, employment issues, emotional and psychological issues, and ease in maintaining a healthy lifestyle.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6690e660>The approach to anti-granulomatous therapy for acute untreated pulmonary sarcoidosis</h2><p class="" id=d6690e663>Acute pulmonary sarcoidosis is a form of the disease that causes worsening pulmonary symptoms and dysfunction over weeks to months and is thought to result from the formation of new granulomas within the lung or growth of existing pulmonary granulomas<sup><a href="#ref-53">53</a></sup>. Obviously, anti-granulomatous therapy is a rational approach to the treatment of this condition. As depicted by the black arrows in <a href="#f2">Figure 2</a>, the sarcoidosis granulomas deposit in involved organs such as the lung and impair normal physiology. These physiologic derangements may lead to functional and QOL impairment. As previously mentioned, the correlations between sarcoidosis-induced granulomatous inflammation and physiologic derangements and between physiologic derangements and QOL impairment are weak.</p><p class="" id=d6690e673>Obviously, patients with pulmonary sarcoidosis should be considered for anti-granulomatous therapy only if they have evidence of active granulomatous inflammation. <a href="#T2">Table 2</a> lists clinical criteria that have been used to determine that granulomatous inflammation is present. These criteria have been used by clinicians to decide when to treat pulmonary sarcoidosis with anti-granulomatous therapy and as entry criteria in pulmonary sarcoidosis trials of anti-granulomatous drugs<sup><a href="#ref-54">54</a>–<a href="#ref-58">58</a></sup>. However, as previously mentioned, because the granulomatous inflammation of sarcoidosis may not progress or even spontaneously resolve without therapy and therapy is associated with significant toxicity, treatment of acute pulmonary sarcoidosis also requires that the condition has resulted in a significant impairment of QOL.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Methods to determine the presence of active pulmonary sarcoidosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6690e697 class=n-a></a><thead><a name=d6690e699 class=n-a></a><tr><a name=d6690e701 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e703 class=n-a></a>Method</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e706 class=n-a></a>Reliability in reflecting active<br class=br>pulmonary granulomatous<br class=br>inflammation</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e713 class=n-a></a>Positive features</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e716 class=n-a></a>Negative features</th></tr></thead><tbody><a name=d6690e721 class=n-a></a><tr><a name=d6690e723 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e725 class=n-a></a>Development of pulmonary<br class=br>symptoms: cough, dyspnea,<br class=br>wheeze, and chest pain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e732 class=n-a></a>++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e735 class=n-a></a>Focuses on the pulmonary<br class=br>physiologic impact of the<br class=br>disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e742 class=n-a></a>Pulmonary symptoms are not highly<br class=br>sensitive or specific for acute pulmonary<br class=br>sarcoidosis. They may represent<br class=br>alternative pulmonary conditions<br class=br>or permanent fibrotic change from<br class=br>previously active pulmonary sarcoidosis</td></tr><tr><a name=d6690e756 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e758 class=n-a></a>Serum biomarkers</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e761 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e764 class=n-a></a>Quantifiable. Directly reflect the<br class=br>total body granuloma burden</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e769 class=n-a></a>Not specific for granulomatous<br class=br>inflammation in the lung</td></tr><tr><a name=d6690e775 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e777 class=n-a></a>Bronchoalveolar lavage fluid<br class=br>findings (lymphocytosis and<br class=br>elevated CD4/CD8 ratio)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e784 class=n-a></a>++++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e787 class=n-a></a>Directly reflects the pulmonary<br class=br>inflammation burden</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e792 class=n-a></a>Cumbersome and relatively invasive</td></tr><tr><a name=d6690e796 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e798 class=n-a></a>Changes in chest imaging</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e801 class=n-a></a>++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e804 class=n-a></a>Specific radiographic findings<br class=br>are highly specific for active<br class=br>lung inflammation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e811 class=n-a></a>Often insensitive to significant change,<br class=br>especially in the case of chest<br class=br>radiographs. Chest CT scans pose a<br class=br>significant radiation risk</td></tr><tr><a name=d6690e821 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e823 class=n-a></a>Positive FDG uptake on lung<br class=br>PET scan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e828 class=n-a></a>++++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e831 class=n-a></a>Specifically reflects active lung<br class=br>inflammation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e836 class=n-a></a>The threshold for clinical significance of<br class=br>the change in FDG uptake is unknown</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6690e846 class=n-a></a><p id=d6690e848> CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography; +, fair; ++, fair-good: ++++, excellent.</p></div></div></div><p class="" id=d6690e854><a href="#f3">Figure 3</a> shows the effect of corticosteroid therapy on pulmonary function for acute untreated pulmonary sarcoidosis. Corticosteroids are most commonly used as initial treatment for acute untreated pulmonary sarcoidosis because they work almost universally and work more rapidly than other medications. If no fibrosis has developed, effective granulomatous therapy should extinguish all granulomatous inflammation and return lung tissue to its normal state, resulting in complete resolution of physiologic impairment. Although resolution of pulmonary physiologic impairment might resolve QOL and functional impairment, this may not be the case because of the potential for the patient to develop numerous corticosteroid side effects. <a href="#f4">Figure 4</a> shows a hypothetical relationship between the efficacy of corticosteroids in resolving the granulomatous inflammation of sarcoidosis and the risks of corticosteroid toxicity. Although high doses of corticosteroids are effective in suppressing granulomatous inflammation, they accomplish this by placing the patient at high risk of corticosteroid side effects. The clinician often attempts to locate a “sweet spot” daily dose of corticosteroids where granulomatous inflammation is adequately suppressed without inducing significant corticosteroid toxicity. Because many of the side effects of corticosteroids (for example, weight gain, osteoporosis, and cataract formation) are cumulative, the duration of corticosteroid therapy may affect the tolerable maximum daily dose of corticosteroids that can be safely used. For this reason, it has been advocated that the daily corticosteroid dose be tapered for pulmonary sarcoidosis cases that have responded to therapy. Although intermittent short courses of corticosteroids may be effective in these instances, acute relapses of pulmonary sarcoidosis are very common such that this treatment approach is rarely satisfactory<sup><a href="#ref-59">59</a></sup>.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure3.gif"><img alt="733a038f-6b2e-4d95-ae42-3f58fab3909a_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure3.gif"></a><div class=caption><h3>Figure 3. The effect on pulmonary function of corticosteroids for untreated, active pulmonary sarcoidosis.</h3><p id=d6690e877>Treatment of the granulomatous inflammation of pulmonary sarcoidosis (blue arrows) with corticosteroids (black arrow) should result in clearance of the deposited granulomas within the lung and return pulmonary function back to normal if no appreciable lung fibrosis has yet developed. It is important to note that, because of potential corticosteroid drug toxicities, such therapy may not resolve quality-of-life issues.</p></div></div><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure4.gif"><img alt="733a038f-6b2e-4d95-ae42-3f58fab3909a_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure4.gif"></a><div class=caption><h3>Figure 4. The relationship between corticosteroid dose and pulmonary granulomatous activity (black line) and risk of corticosteroid toxicity (red line) for the treatment of pulmonary sarcoidosis.</h3><p id=d6690e894>Increasing corticosteroid doses are more effective in resolving granulomatous inflammation at the cost of a greater risk of corticosteroid toxicity. The clinician attempts to locate a “sweet spot” (green dot) where anti-granulomatous efficacy is significant without appreciably raising the risk of corticosteroid side effects.</p></div></div><p class="" id=d6690e901>The endpoints for the treatment of acute untreated pulmonary sarcoidosis should include all three of the following: (a) improvement/resolution of granulomatous inflammation, (b) improvement in pulmonary physiology, and (c) improvement in function status or QOL or both. The rationale for this is explained in <a href="#T3">Table 3</a>, where it is demonstrated that when any one of these endpoints is not reached, the benefit of treatment of acute untreated pulmonary sarcoidosis is questionable. This does not imply that each clinical pulmonary sarcoidosis trial must incorporate all of these endpoints. For example, if a drug therapy has been previously demonstrated to reliably reduce or eliminate the granulomatous inflammation of sarcoidosis, it may not be necessary to demonstrate this endpoint in a clinical trial, although evidence of granulomatous inflammation should be a requirement for study entry.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Assessment of clinical responses to an anti-granulomatous intervention for acute pulmonary sarcoidosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6690e918 class=n-a></a><thead><a name=d6690e920 class=n-a></a><tr><a name=d6690e922 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e924 class=n-a></a>Granulomatous<br class=br>inflammation</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e929 class=n-a></a>Organ function/<br class=br>Physiology</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e934 class=n-a></a>HRQL/function</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e937 class=n-a></a>Usefulness of the intervention</th></tr></thead><tbody><a name=d6690e942 class=n-a></a><tr><a name=d6690e944 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e946 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e949 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e952 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e955 class=n-a></a>Potentially useful</td></tr><tr><a name=d6690e959 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e961 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e964 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e967 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e970 class=n-a></a>Not clinically useful</td></tr><tr><a name=d6690e974 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e976 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e979 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e982 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e985 class=n-a></a>Potentially useful, but the mechanism of action may be<br class=br>unclear (for example, corticosteroids causing euphoria)</td></tr><tr><a name=d6690e991 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e993 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e996 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e999 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1002 class=n-a></a>Not clinically useful</td></tr><tr><a name=d6690e1006 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1008 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1011 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1014 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1017 class=n-a></a>Potentially useful, but the mechanism of action may be<br class=br>unclear (for example, treatment of heart failure or obesity)</td></tr><tr><a name=d6690e1024 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1026 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1029 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1032 class=n-a></a>− </td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1035 class=n-a></a>Not clinically useful</td></tr><tr><a name=d6690e1039 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1041 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1044 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1047 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1050 class=n-a></a>Potentially useful, but the mechanism of action may be<br class=br>unclear (for example, corticosteroids causing euphoria)</td></tr><tr><a name=d6690e1056 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1058 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1061 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1064 class=n-a></a>−</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1067 class=n-a></a>Not clinically useful</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6690e1075 class=n-a></a><p id=d6690e1077> HRQL, health-related quality of life; +, present; -, absent.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6690e1086>The approach to anti-granulomatous therapy for chronically treated pulmonary sarcoidosis</h2><p class="" id=d6690e1089>Because corticosteroids are highly efficacious for pulmonary sarcoidosis, additional anti-granulomatous agents are often used as corticosteroid-sparing agents in order to lower the corticosteroid dose requirement. Additional agents can also be used to provide further anti-granulomatous therapy on top of corticosteroids, although often the additional benefit of such agents is minimal in pulmonary sarcoidosis patients receiving more than 10 to 15 mg of prednisone per day<sup><a href="#ref-60">60</a></sup>. <a href="#f5">Figure 5</a> outlines how a corticosteroid-sparing agent can effectively decrease the corticosteroid dose sweet spot in terms of the benefits of corticosteroid therapy versus the risks of corticosteroid toxicity. A majority of 36 sarcoidosis experts believed that a chronic daily maintenance dose of more than 10 mg of prednisone was unacceptable and mandated consideration of corticosteroid-sparing therapy<sup><a href="#ref-61">61</a></sup>. For pulmonary sarcoidosis, these corticosteroid-sparing agents include anti-metabolites such as methotrexate<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>, azathioprine<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>, and the tumor necrosis factor-alpha (TNF-α) antagonists infliximab<sup><a href="#ref-56">56</a></sup> and adalimumab<sup><a href="#ref-66">66</a></sup>. These agents usually are used as second- or third-line agents that are added on to corticosteroid therapy because they either take weeks to months longer than corticosteroids to be effective<sup><a href="#ref-63">63</a>,<a href="#ref-65">65</a></sup> or—in the case of the TNF-α antagonists—are much more expensive than corticosteroids.</p><a name=f5 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure5.gif"><img alt="733a038f-6b2e-4d95-ae42-3f58fab3909a_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure5.gif"></a><div class=caption><h3>Figure 5. The rationale for adding a corticosteroid-sparing drug for the treatment of pulmonary sarcoidosis.</h3><p id=d6690e1143>A corticosteroid-sparing drug has some anti-granulomatous activity such that a lower dose of corticosteroids (blue line) is needed to achieve the same level of granulomatous activity as without use of the corticosteroid-sparing medication (black line). This results in lowering the sweet spot for the ideal corticosteroid dose (from the green dot to the blue dot).</p></div></div><p class="" id=d6690e1150>Entry criteria for anti-granulomatous therapy trials for patients with chronically treated pulmonary sarcoidosis should include evidence of granulomatous inflammation, physiologic impairment, and functional/QOL impairment at study entry or—if a corticosteroid withdrawal phase of the trial is planned—historical evidence of these abnormalities when the corticosteroid dose is lowered. <a href="#f6">Figure 6</a> outlines the effect on pulmonary physiology with the addition of a corticosteroid-sparing anti-granulomatous agent for chronically treated pulmonary sarcoidosis. Because corticosteroids are effective anti-granulomatous agents, there is often relatively little residual granulomatous inflammation that requires additional therapy. The prototypical chronic pulmonary sarcoidosis patient enrolled in a clinical trial is receiving chronic corticosteroid therapy. The patient’s pulmonary function has usually waxed and waned over time, depending on the dose of corticosteroids and other anti-granulomatous drug therapy. The pulmonary function of these patients may decline if their granulomatous inflammation is undertreated, and they may develop permanent reductions in pulmonary function from the development of pulmonary fibrosis. However, this fibrosis rarely causes a rapid decline in physiology, as evidenced by the fact that the placebo group in several trials where all subjects were receiving a maintenance corticosteroid medication in addition to a study drug did not demonstrate a significant reduction in spirometry over a study period of 4 months or more<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>.</p><a name=f6 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure6.gif"><img alt="733a038f-6b2e-4d95-ae42-3f58fab3909a_figure6.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure6.gif"></a><div class=caption><h3>Figure 6. The effect on pulmonary function of adding an additional anti-granulomatous drug to corticosteroid treatment for chronically treated pulmonary sarcoidosis.</h3><p id=d6690e1173>There is usually minimal residual granulomatous inflammation in patients who receive corticosteroids such that there is a small potential for further significant physiologic improvement (green double arrow). It is important to note that although additional drug therapy may not greatly improve physiology, it may significantly improve quality of life by reducing corticosteroid side effects if addition drugs are corticosteroid-sparing.</p></div></div><p class="" id=d6690e1181>For these reasons, the endpoints of trials for acute untreated pulmonary sarcoidosis are not highly relevant to evaluate anti-granulomatous drugs used in chronically treated pulmonary sarcoidosis patients. There is often little granulomatous inflammation left to treat, and the issue is whether the drug will continue to suppress granulomatous inflammation when the corticosteroid dose is lowered. The same could be said for the physiologic endpoint: the issue is often not whether the additional drug will improve pulmonary physiology but rather whether it will allow the pulmonary physiology to be maintained as the corticosteroid dose is lowered. The QOL endpoint is still highly relevant, especially in terms of a reduction of corticosteroid side effects. <a href="#T4">Table 4</a> outlines potential endpoints for a trial of anti-granulomatous therapy for chronically treated pulmonary sarcoidosis.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Potential endpoints for trial of anti-granulomatous therapy for chronically treated pulmonary sarcoidosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6690e1198 class=n-a></a><thead><a name=d6690e1200 class=n-a></a><tr><a name=d6690e1202 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1204 class=n-a></a>Endpoint</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1207 class=n-a></a>Relevance</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1210 class=n-a></a>Positive features</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1213 class=n-a></a>Negative features</th></tr></thead><tbody><a name=d6690e1218 class=n-a></a><tr><a name=d6690e1220 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1222 class=n-a></a>Granulomatous inflammation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1225 class=n-a></a>++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1228 class=n-a></a>Examines the anti-<br class=br>granulomatous activity of<br class=br>the drug</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1235 class=n-a></a>There is often minimal residual granulomatous<br class=br>activity remaining to treat. It is problematic to<br class=br>define a reduction in granulomatous inflammation<br class=br>that is significant.</td></tr><tr><a name=d6690e1245 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1247 class=n-a></a>Pulmonary physiology</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1250 class=n-a></a>++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1253 class=n-a></a>Examines the physiologic<br class=br>impact of the drug</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1258 class=n-a></a>Improvement in physiology correlates weakly with<br class=br>functional and quality-of-life improvement. There<br class=br>is often minimal residual physiologic impairment<br class=br>remaining to treat.</td></tr><tr><a name=d6690e1268 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1270 class=n-a></a>Reduction in exacerbations of<br class=br>acute pulmonary sarcoidosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1275 class=n-a></a>+++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1278 class=n-a></a>Often a major concern of<br class=br>patients and clinicians</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1283 class=n-a></a>Acute pulmonary exacerbations of sarcoidosis<br class=br>are often problematic to differentiate from other<br class=br>pulmonary conditions.</td></tr><tr><a name=d6690e1291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1293 class=n-a></a>Reduction in corticosteroid<br class=br>dose/corticosteroid side effects</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1298 class=n-a></a>++++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1301 class=n-a></a>Often a major concern of<br class=br>patients and clinicians</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1306 class=n-a></a>A corticosteroid reduction may be successful<br class=br>when the study drug is not active if the underlying<br class=br>granulomatous inflammation of sarcoidosis has<br class=br>lessened or resolved.</td></tr><tr><a name=d6690e1316 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1318 class=n-a></a>Improved functional status/<br class=br>quality of life</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1323 class=n-a></a>++++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1326 class=n-a></a>Usually the major concern<br class=br>of patients and clinicians</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1331 class=n-a></a>The improved functional status/quality of life may<br class=br>not be health-related. </td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6690e1341 class=n-a></a><p id=d6690e1343> ++, somewhat relevant; +++, relevant; ++++, highly relevant.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6690e1352>The approach to therapy for fibrotic pulmonary sarcoidosis</h2><p class="" id=d6690e1355>As previously mentioned, it is conjectured that the fibrosis in sarcoidosis is the result of granulomatous inflammation. The relationship of granulomatous inflammation, pulmonary fibrosis, and treatment of pulmonary sarcoidosis is depicted in <a href="#f7">Figure 7</a>. The amount of fibrosis that develops with pulmonary sarcoidosis is highly variable and is essentially unpredictable in individual patients (<a href="#f7">Figure 7A</a>). The physiologic defects that develop from fibrosis in pulmonary sarcoidosis are permanent and will not respond to anti-granulomatous therapy or any other therapies that are currently available (<a href="#f7">Figure 7B</a>).</p><a name=f7 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure7.gif"><img alt="733a038f-6b2e-4d95-ae42-3f58fab3909a_figure7.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22762/733a038f-6b2e-4d95-ae42-3f58fab3909a_figure7.gif"></a><div class=caption><h3>Figure 7. Development and treatment of pulmonary fibrosis in sarcoidosis.</h3><p id=d6690e1377><b>(A)</b> Development and progression of pulmonary fibrosis in a patient with active pulmonary sarcoidosis. The granulomatous inflammation of sarcoidosis may result in worsening pulmonary symptoms and worsening pulmonary function (blue line). Because the granulomatous inflammation of sarcoidosis is the most common cause of pulmonary fibrosis in sarcoidosis, fibrosis may develop as the granulomatous inflammation continues (green line). This fibrosis contributes to worsening pulmonary symptoms and worsening pulmonary dysfunction (red line). In some patients with pulmonary sarcoidosis, the fibrotic reaction to the granulomatous inflammation may be robust (wide dotted line), causing extensive fibrosis early. Other patients with pulmonary sarcoidosis may have a sluggish fibrotic response to the granulomatous inflammation (short dotted line), and the fibrosis is minimal and requires granulomatous inflammation to be active for a longer period of time. Some patients with pulmonary sarcoidosis may not develop fibrosis at all in response to the granulomatous inflammation. <b>(B)</b> The effect of treatment on the granulomatous inflammation and fibrosis associated with pulmonary sarcoidosis. Effective anti-granulomatous therapy will suppress the granulomatous inflammation of sarcoidosis (blue line) and improve the overall pulmonary symptoms and pulmonary function (red line). However, anti-granulomatous therapy will have no effect on the pulmonary symptoms or dysfunction caused by sarcoidosis-related fibrosis (green line). Therefore, successfully treated patients will have their symptomatic and physiologic improvement limited by the degree of pulmonary fibrosis that has developed.</p></div></div><p class="" id=d6690e1389>Therapy for fibrotic pulmonary sarcoidosis is currently aimed at either (a) treating the complications of pulmonary fibrosis or (b) preventing the progression of further lung fibrosis. The complications of pulmonary fibrosis are listed in <a href="#T1">Table 1</a> and include sarcoidosis-associated pulmonary hypertension<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup>, bronchiectasis<sup><a href="#ref-69">69</a>,<a href="#ref-70">70</a></sup>, and pulmonary mycetoma<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. The indications for treatment of these conditions as well as the endpoints to monitor these forms of disease are well covered elsewhere<sup><a href="#ref-69">69</a>,<a href="#ref-71">71</a>,<a href="#ref-73">73</a>–<a href="#ref-75">75</a></sup>. Anti-granulomatous therapy is rarely useful for sarcoidosis-associated pulmonary hypertension and is often detrimental for bronchiectasis and pulmonary mycetoma as it may cause serious infectious complications. As end-stage pulmonary fibrosis is a disabling and life-threatening condition, lung transplantation should be considered in fibrotic pulmonary sarcoidosis patients with limited chance for improvement and minimal extrapulmonary comorbidities<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d6690e1434>In terms of therapy to prevent the development of further fibrosis, it has already been mentioned that the majority of patients with fibrotic pulmonary sarcoidosis have evidence of granulomatous inflammation<sup><a href="#ref-16">16</a>,<a href="#ref-19">19</a></sup>. It is thought that such “smoldering” granulomatous inflammation is the nidus for the development of further fibrosis. Therefore, evidence of granulomatous inflammation would be a prerequisite for instituting anti-granulomatous therapy for fibrotic pulmonary sarcoidosis.</p><p class="" id=d6690e1445>An additional issue when considering treatment of sarcoidosis-associated pulmonary fibrosis is the rapidity of its development. It is thought that fibrosis develops slowly in pulmonary sarcoidosis, such that the cumulative toxicities of long-term anti-sarcoidosis medications, especially corticosteroids, would limit their long-term use. Certainly, evidence of rapid development of pulmonary fibrosis with a concomitant rapid decline in physiology or functional status/QOL would be a strong impetus to consider anti-granulomatous therapy. Because of the toxicity of corticosteroids and other anti-granulomatous therapies, another approach would be to use “downstream” medications targeting the development of fibrosis itself. Such medications include pirfenidone and nintedanib, which have been shown to decelerate the development of lung fibrosis in idiopathic pulmonary fibrosis and other interstitial lung diseases<sup><a href="#ref-77">77</a>–<a href="#ref-79">79</a></sup>.</p><p class="" id=d6690e1455>In terms of endpoints for the treatment of fibrotic pulmonary sarcoidosis, improvements in pulmonary function and functional status/QOL from anti-granulomatous therapy may be significant yet are unlikely to be large because improvement in the patient’s pulmonary function is unlikely to be great<sup><a href="#ref-57">57</a></sup>. The ablation of granulomatous inflammation may improve QOL by reducing symptoms derived from parasarcoidosis syndromes that may be indirectly derived from granulomatous inflammation (see below). However, other useful endpoints for the treatment of fibrotic pulmonary sarcoidosis may reflect a lack of deterioration of patient status. <a href="#T5">Table 5</a> shows potential indications for the treatment of fibrotic pulmonary sarcoidosis, and <a href="#T6">Table 6</a> shows potential endpoints of treatment for fibrotic pulmonary sarcoidosis.</p><a name=T5 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 5. Potential indications for treatment of fibrotic pulmonary sarcoidosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6690e1479 class=n-a></a><thead><a name=d6690e1481 class=n-a></a><tr><a name=d6690e1483 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1485 class=n-a></a>Indication for treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1488 class=n-a></a>Rationale</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1491 class=n-a></a>Negative features</th></tr></thead><tbody><a name=d6690e1496 class=n-a></a><tr><a name=d6690e1498 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1500 class=n-a></a>The presence of granulomatous<br class=br>inflammation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1505 class=n-a></a>Treating active granulomatous<br class=br>inflammation in fibrotic pulmonary<br class=br>sarcoidosis improves physiology</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1512 class=n-a></a>Fibrosis in sarcoidosis usually develops slowly such<br class=br>that obliteration of granulomatous inflammation<br class=br>may have a minimal appreciable effect on the<br class=br>development of fibrosis.</td></tr><tr><a name=d6690e1522 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1524 class=n-a></a>Significant impairment in functional<br class=br>status or quality of life from previous<br class=br>pulmonary fibrosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1531 class=n-a></a>Usually the major concern of patients<br class=br>and clinicians</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1536 class=n-a></a>No anti-fibrotic therapy that lessens the degree of<br class=br>pulmonary fibrosis is currently available.</td></tr><tr><a name=d6690e1542 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1544 class=n-a></a>Relatively rapid decline in functional<br class=br>status or quality of life impairment<br class=br>from pulmonary fibrosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1551 class=n-a></a>Usually the major concern of patients<br class=br>and clinicians</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1556 class=n-a></a>No anti-fibrotic therapy for pulmonary sarcoidosis is<br class=br>currently available.</td></tr><tr><a name=d6690e1562 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1564 class=n-a></a>Development of a condition<br class=br>associated with fibrotic pulmonary<br class=br>sarcoidosis (<a href="#T1">Table 1</a>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1574 class=n-a></a>These conditions may cause<br class=br>significant impairment of quality of<br class=br>life or dangerous conditions or both</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1581 class=n-a></a>Most of these treatments are for complications of<br class=br>pulmonary fibrosis and do not directly treat the<br class=br>presence or worsening of pulmonary fibrosis.</td></tr></tbody></table></div><a name=T6 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 6. Potential endpoints for fibrotic pulmonary sarcoidosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6690e1603 class=n-a></a><thead><a name=d6690e1605 class=n-a></a><tr><a name=d6690e1607 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1609 class=n-a></a>Endpoint</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1612 class=n-a></a>Clinical<br class=br>usefulness</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1617 class=n-a></a>Positive features</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6690e1620 class=n-a></a>Negative features</th></tr></thead><tbody><a name=d6690e1625 class=n-a></a><tr><a name=d6690e1627 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1629 class=n-a></a>Resolution of granulomatous<br class=br>inflammation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1634 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1637 class=n-a></a>Strongly suggests that the profibrotic<br class=br>response has been ablated</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1642 class=n-a></a>Problematic to quantify degree of reduction of<br class=br>granulomatous inflammation</td></tr><tr><a name=d6690e1648 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1650 class=n-a></a>Time to clinical worsening of<br class=br>pulmonary function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1655 class=n-a></a>++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1658 class=n-a></a>Suggests that intervention is<br class=br>decelerating the physiologic decline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1663 class=n-a></a>Correlation of physiology to functional status and<br class=br>quality of life is poor; development of pulmonary<br class=br>fibrosis is slow such that it may take a long time to<br class=br>detect significant differences</td></tr><tr><a name=d6690e1673 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1675 class=n-a></a>Time to clinical worsening of<br class=br>functional status or quality of life</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1680 class=n-a></a>+++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1683 class=n-a></a>Usually the major concern of patients<br class=br>and clinicians</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1688 class=n-a></a>Development of pulmonary fibrosis is slow such<br class=br>that it may take a long time to detect significant<br class=br>change; problematic to distinguish health-related<br class=br>from health-unrelated quality-of-life effects </td></tr><tr><a name=d6690e1698 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1700 class=n-a></a>Reduction in corticosteroid<br class=br>dose/corticosteroid side effects</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1705 class=n-a></a>+++</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1708 class=n-a></a>Often a major concern of patients<br class=br>and clinicians</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6690e1713 class=n-a></a>A corticosteroid reduction may be successful<br class=br>when a drug is ineffective if the underlying<br class=br>granulomatous inflammation of sarcoidosis has<br class=br>lessened or resolved</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6690e1727 class=n-a></a><p id=d6690e1729> +, poor to somewhat useful; ++, useful; +++, very useful.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6690e1739>Summary</h2><p class="" id=d6690e1742>The physiologic impairment resulting from the granulomatous inflammation of pulmonary sarcoidosis is highly variable. Even more variable is the effect of these physiologic derangements on the QOL of the patient with pulmonary sarcoidosis. This granulomatous inflammation can also adversely affect the QOL of the patient with sarcoidosis by systemic mechanisms other than direct deposition of granulomas into specific organs (“parasarcoidosis syndromes”). Additionally, this granulomatous inflammation may lead to the development of pulmonary fibrosis that causes irreversible pulmonary dysfunction and, potentially, disabling and life-threatening situations. Finally, anti-granulomatous therapy not only may improve the QOL of the patient with pulmonary sarcoidosis by effectively treating the disease but also may worsen it by causing serious drug side effects. We have proposed a conceptual framework to outline how these many factors interact to cause physiologic and QOL impairments in pulmonary sarcoidosis. We believe that this conceptual framework may be useful in constructing a clinical drug trial for pulmonary sarcoidosis that reflects the concerns of patients and clinicians.</p><p class="" id=d6690e1745>Because of numerous aspects of pulmonary sarcoidosis and its therapy, it is not surprising that developing treatment indications and endpoints for the therapy of the disease is challenging. We have made a case for partitioning patients into three treatment groups when considering indications for therapy as well as therapy endpoints: untreated patients with active granulomatous inflammation, patients with chronically treated disease, and those with significant lung fibrosis. It is hoped that this proposed patient partitioning will stimulate debate and constructive criticism that will eventually lead to therapy for pulmonary sarcoidosis that is better directed in treating the true concerns of patients.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d6690e1752 class=n-a></a><h2 class=main-title id=d6690e1754>Acknowledgments</h2><p class="" id=d6690e1757>The author wishes to thank Sooyeon Kwon (The Center of Rheumatology), PhD, for her expert assistance in terms of suggestions and preparation of the tables in this article.</p></div><div class=back-section><a name=d6690e1761 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d7162>References</h2><div class="section ref-list"><a name=d6690e1761 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d6690e1768 class=n-a></a>James WE, Koutroumpakis E, Saha B, <i> et al.</i>: Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. <i>Chest.</i> 2018; <b>154</b>(2): 349–56. <a target=xrefwindow id=d6690e1779 href="http://www.ncbi.nlm.nih.gov/pubmed/29453944">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1782 href="https://doi.org/10.1016/j.chest.2018.02.003">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d6690e1791 class=n-a></a>Judson MA: The Clinical Features of Sarcoidosis: A Comprehensive Review. <i>Clin Rev Allergy Immunol.</i> 2015; <b>49</b>(1): 63–78. <a target=xrefwindow id=d6690e1799 href="http://www.ncbi.nlm.nih.gov/pubmed/25274450">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1802 href="https://doi.org/10.1007/s12016-014-8450-y">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d6690e1811 class=n-a></a>Judson MA: Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. <i>Expert Rev Respir Med.</i> 2017; <b>11</b>(2): 111–8. <a target=xrefwindow id=d6690e1819 href="http://www.ncbi.nlm.nih.gov/pubmed/28076979">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1822 href="https://doi.org/10.1080/17476348.2017.1281745">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d6690e1831 class=n-a></a>Chopra A, Kalkanis A, Judson MA: Biomarkers in sarcoidosis. <i>Expert Rev Clin Immunol.</i> 2016; <b>12</b>(11): 1191–208. <a target=xrefwindow id=d6690e1839 href="http://www.ncbi.nlm.nih.gov/pubmed/27253883">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1842 href="https://doi.org/10.1080/1744666X.2016.1196135">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d6690e1851 class=n-a></a>Buchman AL: Side effects of corticosteroid therapy. <i>J Clin Gastroenterol.</i> 2001; <b>33</b>(4): 289–94. <a target=xrefwindow id=d6690e1859 href="http://www.ncbi.nlm.nih.gov/pubmed/11588541">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1862 href="https://doi.org/10.1097/00004836-200110000-00006">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d6690e1872 class=n-a></a>Moller DR: Negative clinical trials in sarcoidosis: failed therapies or flawed study design? <i>Eur Respir J.</i> 2014; <b>44</b>(5): 1123–6. <a target=xrefwindow id=d6690e1880 href="http://www.ncbi.nlm.nih.gov/pubmed/25362122">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1883 href="https://doi.org/10.1183/09031936.00156314">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d6690e1892 class=n-a></a>Baughman RP, Judson MA, Wells AU: The indications for the treatment of sarcoidosis: Well’s Law. <i>Sarcoidosis Vasc Diff Lung Dis.</i> 2017; <b>34</b>: 280–284. <a target=xrefwindow id=d6690e1900 href="https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/6954/4739">Reference Source</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d6690e1909 class=n-a></a>Judson MA, Boan AD, Lackland DT: The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2012; <b>29</b>(2): 119–27. <a target=xrefwindow id=d6690e1917 href="http://www.ncbi.nlm.nih.gov/pubmed/23461074">PubMed Abstract </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717697808"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e1926 class=n-a></a>Shlobin OA, Nathan SD: Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. <i>Eur Respir J.</i> 2012; <b>39</b>(6): 1520–33. <a target=xrefwindow id=d6690e1934 href="http://www.ncbi.nlm.nih.gov/pubmed/22241743">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1937 href="https://doi.org/10.1183/09031936.00175511">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717697808">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d6690e1950 class=n-a></a>Patterson KC, Hogarth K, Husain AN, <i> et al.</i>: The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. <i>Transl Res.</i> 2012; <b>160</b>(5): 321–31. <a target=xrefwindow id=d6690e1961 href="http://www.ncbi.nlm.nih.gov/pubmed/22683422">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1964 href="https://doi.org/10.1016/j.trsl.2012.03.005">Publisher Full Text </a> | <a target=xrefwindow id=d6690e1968 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3910531">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d6690e1977 class=n-a></a>Prasse A, Pechkovsky DV, Toews GB, <i> et al.</i>: A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. <i>Am J Respir Crit Care Med.</i> 2006; <b>173</b>(7): 781–92. <a target=xrefwindow id=d6690e1988 href="http://www.ncbi.nlm.nih.gov/pubmed/16415274">PubMed Abstract </a> | <a target=xrefwindow id=d6690e1991 href="https://doi.org/10.1164/rccm.200509-1518OC">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d6690e2001 class=n-a></a>Moller DR: Pulmonary fibrosis of sarcoidosis. New approaches, old ideas. <i>Am J Respir Cell Mol Biol.</i> 2003; <b>29</b>(3 Suppl): S37–41. <a target=xrefwindow id=d6690e2009 href="http://www.ncbi.nlm.nih.gov/pubmed/14503552">PubMed Abstract </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d6690e2018 class=n-a></a>Kruit A, Grutters JC, Ruven HJ, <i> et al.</i>: Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. <i>Chest.</i> 2006; <b>129</b>(6): 1584–91. <a target=xrefwindow id=d6690e2029 href="http://www.ncbi.nlm.nih.gov/pubmed/16778279">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2032 href="https://doi.org/10.1378/chest.129.6.1584">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d6690e2041 class=n-a></a>Koth LL, Solberg OD, Peng JC, <i> et al.</i>: Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. <i>Am J Respir Crit Care Med.</i> 2011; <b>184</b>(10): 1153–63. <a target=xrefwindow id=d6690e2052 href="http://www.ncbi.nlm.nih.gov/pubmed/21852540">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2055 href="https://doi.org/10.1164/rccm.201106-1143OC">Publisher Full Text </a> | <a target=xrefwindow id=d6690e2059 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3262024">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732451430"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2068 class=n-a></a>Le V, Crouser ED: Potential immunotherapies for sarcoidosis. <i>Expert Opin Biol Ther.</i> 2018; <b>18</b>(4): 399–407. <a target=xrefwindow id=d6690e2076 href="http://www.ncbi.nlm.nih.gov/pubmed/29327613">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2079 href="https://doi.org/10.1080/14712598.2018.1427727">Publisher Full Text </a> | <a target=xrefwindow id=d6690e2082 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6171107">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732451430">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725624169"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2095 class=n-a></a>Zhang C, Chan KM, Schmidt LA, <i> et al.</i>: Histopathology of Explanted Lungs From Patients With a Diagnosis of Pulmonary Sarcoidosis. <i>Chest.</i> 2016; <b>149</b>(2): 499–507. <a target=xrefwindow id=d6690e2106 href="http://www.ncbi.nlm.nih.gov/pubmed/26158549">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2109 href="https://doi.org/10.1378/chest.15-0615">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725624169">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725139367"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2122 class=n-a></a>Abehsera M, Valeyre D, Grenier P, <i> et al.</i>: Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. <i>AJR Am J Roentgenol.</i> 2000; <b>174</b>(6): 1751–7. <a target=xrefwindow id=d6690e2133 href="http://www.ncbi.nlm.nih.gov/pubmed/10845518">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2136 href="https://doi.org/10.2214/ajr.174.6.1741751">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725139367">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d6690e2150 class=n-a></a>Xu L, Kligerman S, Burke A: End-stage sarcoid lung disease is distinct from usual interstitial pneumonia. <i>Am J Surg Pathol.</i> 2013; <b>37</b>(4): 593–600. <a target=xrefwindow id=d6690e2158 href="http://www.ncbi.nlm.nih.gov/pubmed/23426125">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2161 href="https://doi.org/10.1097/PAS.0b013e3182785a2d">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717984411"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2170 class=n-a></a>Mostard RLM, Verschakelen JA, van Kroonenburgh MJ, <i> et al.</i>: Severity of pulmonary involvement and <sup>18</sup>F-FDG PET activity in sarcoidosis. <i>Respir Med.</i> 2013; <b>107</b>(3): 439–47. <a target=xrefwindow id=d6690e2184 href="http://www.ncbi.nlm.nih.gov/pubmed/23261309">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2188 href="https://doi.org/10.1016/j.rmed.2012.11.011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717984411">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d6690e2201 class=n-a></a>Valeyre D, Bernaudin JF, Jeny F, <i> et al.</i>: Pulmonary Sarcoidosis. <i>Clin Chest Med.</i> 2015; <b>36</b>(4): 631–41. <a target=xrefwindow id=d6690e2212 href="http://www.ncbi.nlm.nih.gov/pubmed/26593138">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2215 href="https://doi.org/10.1016/j.ccm.2015.08.006">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734702889"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2224 class=n-a></a>Baughman RP, Barriuso R, Beyer K, <i> et al.</i>: Sarcoidosis: patient treatment priorities. <i>ERJ Open Res.</i> 2018; <b>4</b>(4): pii: 00141-2018. <a target=xrefwindow id=d6690e2235 href="http://www.ncbi.nlm.nih.gov/pubmed/30588477">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2238 href="https://doi.org/10.1183/23120541.00141-2018">Publisher Full Text </a> | <a target=xrefwindow id=d6690e2242 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6302206">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734702889">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d6690e2255 class=n-a></a>Judson MA: Quality of Life in Sarcoidosis. <i>Semin Respir Crit Care Med.</i> 2017; <b>38</b>(4): 546–58. <a target=xrefwindow id=d6690e2263 href="http://www.ncbi.nlm.nih.gov/pubmed/28750468">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2266 href="https://doi.org/10.1055/s-0037-1602589">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d6690e2275 class=n-a></a>Judson MA: Quality of Life Assessment in Sarcoidosis. <i>Clin Chest Med.</i> 2015; <b>36</b>(4): 739–50. <a target=xrefwindow id=d6690e2283 href="http://www.ncbi.nlm.nih.gov/pubmed/26593146">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2286 href="https://doi.org/10.1016/j.ccm.2015.08.014">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d6690e2296 class=n-a></a>Rømer FK: Presentation of sarcoidosis and outcome of pulmonary changes. <i>Dan Med Bull.</i> 1982; <b>29</b>(1): 27–32. <a target=xrefwindow id=d6690e2304 href="http://www.ncbi.nlm.nih.gov/pubmed/7067499">PubMed Abstract </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d6690e2313 class=n-a></a>Baydur A, Alsalek M, Louie SG, <i> et al.</i>: Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. <i>Chest.</i> 2001; <b>120</b>(1): 102–8. <a target=xrefwindow id=d6690e2324 href="http://www.ncbi.nlm.nih.gov/pubmed/11451823">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2327 href="https://doi.org/10.1378/chest.120.1.102">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d6690e2336 class=n-a></a>Cox CE, Donohue JF, Brown CD, <i> et al.</i>: The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. <i>Am J Respir Crit Care Med.</i> 2003; <b>168</b>(3): 323–9. <a target=xrefwindow id=d6690e2347 href="http://www.ncbi.nlm.nih.gov/pubmed/12738606">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2350 href="https://doi.org/10.1164/rccm.200211-1343OC">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d6690e2359 class=n-a></a>Cox CE, Donohue JF, Brown CD, <i> et al.</i>: Health-related quality of life of persons with sarcoidosis. <i>Chest.</i> 2004; <b>125</b>(3): 997–1004. <a target=xrefwindow id=d6690e2370 href="http://www.ncbi.nlm.nih.gov/pubmed/15006960">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2373 href="https://doi.org/10.1378/chest.125.3.997">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d6690e2382 class=n-a></a>Baughman RP, Nunes H, Sweiss NJ, <i> et al.</i>: Established and experimental medical therapy of pulmonary sarcoidosis. <i>Eur Respir J.</i> 2013; <b>41</b>(6): 1424–38. <a target=xrefwindow id=d6690e2393 href="http://www.ncbi.nlm.nih.gov/pubmed/23397302">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2396 href="https://doi.org/10.1183/09031936.00060612">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d6690e2405 class=n-a></a>Judson MA: Corticosteroids in Sarcoidosis. <i>Rheum Dis Clin North Am.</i> 2016; <b>42</b>(1): 119–35, ix. <a target=xrefwindow id=d6690e2413 href="http://www.ncbi.nlm.nih.gov/pubmed/26611555">PubMed Abstract </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732308014"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2423 class=n-a></a>Khan NA, Donatelli CV, Tonelli AR, <i> et al.</i>: Toxicity risk from glucocorticoids in sarcoidosis patients. <i>Respir Med.</i> 2017; <b>132</b>: 9–14. <a target=xrefwindow id=d6690e2434 href="http://www.ncbi.nlm.nih.gov/pubmed/29229111">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2437 href="https://doi.org/10.1016/j.rmed.2017.09.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732308014">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d6690e2450 class=n-a></a>Judson MA, Chaudhry H, Louis A, <i> et al.</i>: The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. <i>Respir Med.</i> 2015; <b>109</b>(4): 526–31. <a target=xrefwindow id=d6690e2461 href="http://www.ncbi.nlm.nih.gov/pubmed/25698652">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2464 href="https://doi.org/10.1016/j.rmed.2015.01.019">Publisher Full Text </a> | <a target=xrefwindow id=d6690e2468 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4447298">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d6690e2477 class=n-a></a>Cella DF, Bonomi AE: Measuring quality of life: 1995 update. <i>Oncology (Williston Park).</i> 1995; <b>9</b>(11 Suppl): 47–60. <a target=xrefwindow id=d6690e2485 href="http://www.ncbi.nlm.nih.gov/pubmed/8608056">PubMed Abstract </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d6690e2494 class=n-a></a>Patrick DL, Burke LB, Powers JH, <i> et al.</i>: Patient-reported outcomes to support medical product labeling claims: FDA perspective. <i>Value Health.</i> 2007; <b>10 Suppl 2</b>: S125–37. <a target=xrefwindow id=d6690e2505 href="http://www.ncbi.nlm.nih.gov/pubmed/17995471">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2508 href="https://doi.org/10.1111/j.1524-4733.2007.00275.x">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d6690e2517 class=n-a></a>U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. <i>Health Qual Life Outcomes.</i> 2006; <b>4</b>: 79. <a target=xrefwindow id=d6690e2525 href="http://www.ncbi.nlm.nih.gov/pubmed/17034633">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2528 href="https://doi.org/10.1186/1477-7525-4-79">Publisher Full Text </a> | <a target=xrefwindow id=d6690e2531 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1629006">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d6690e2540 class=n-a></a>Judson MA, Mack M, Beaumont JL, <i> et al.</i>: Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. <i>Am J Respir Crit Care Med.</i> 2015; <b>191</b>(7): 786–95. <a target=xrefwindow id=d6690e2551 href="http://www.ncbi.nlm.nih.gov/pubmed/25594886">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2554 href="https://doi.org/10.1164/rccm.201410-1785OC">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d6690e2564 class=n-a></a>Patel AS, Siegert RJ, Creamer D, <i> et al.</i>: The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. <i>Thorax.</i> 2013; <b>68</b>(1): 57–65. <a target=xrefwindow id=d6690e2575 href="http://www.ncbi.nlm.nih.gov/pubmed/23065052">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2578 href="https://doi.org/10.1136/thoraxjnl-2012-201962">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d6690e2587 class=n-a></a>De Vries J, Michielsen H, Heck GL, <i> et al.</i>: Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). <i>Br J Health Psychol.</i> 2004; <b>9</b>(Pt 3): 279–91. <a target=xrefwindow id=d6690e2598 href="http://www.ncbi.nlm.nih.gov/pubmed/15296678">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2601 href="https://doi.org/10.1348/1359107041557048">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d6690e2610 class=n-a></a>Victorson DE, Cella D, Judson MA: Quality of life evaluation in sarcoidosis: current status and future directions. <i>Curr Opin Pulm Med.</i> 2008; <b>14</b>(5): 470–7. <a target=xrefwindow id=d6690e2618 href="http://www.ncbi.nlm.nih.gov/pubmed/18664978">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2621 href="https://doi.org/10.1097/MCP.0b013e3283050a4f">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d6690e2630 class=n-a></a>Cella D, Nowinski CJ: Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. <i>Arch Phys Med Rehabil.</i> 2002; <b>83</b>(12 Suppl 2): S10–S17. <a target=xrefwindow id=d6690e2638 href="http://www.ncbi.nlm.nih.gov/pubmed/12474167">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2641 href="https://doi.org/10.1053/apmr.2002.36959">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d6690e2650 class=n-a></a>Ware JE Jr, Bjorner JB, Kosinski M: Practical implications of item response theory and computerized adaptive testing: a brief summary of ongoing studies of widely used headache impact scales. <i>Med Care.</i> 2000; <b>38</b>(9 Suppl): II73–82. <a target=xrefwindow id=d6690e2658 href="http://www.ncbi.nlm.nih.gov/pubmed/10982092">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2661 href="https://doi.org/10.1097/00005650-200009002-00011">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d6690e2670 class=n-a></a>Judson MA: The three tiers of screening for sarcoidosis organ involvement. <i>Respir Med.</i> 2016; <b>113</b>: 42–9. <a target=xrefwindow id=d6690e2678 href="http://www.ncbi.nlm.nih.gov/pubmed/27021579">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2681 href="https://doi.org/10.1016/j.rmed.2016.02.011">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d6690e2691 class=n-a></a>Wanat KA, Rosenbach M: Cutaneous sarcoidosis. <i>Clin Chest Med.</i> 2015; <b>36</b>(4): 685–702. <a target=xrefwindow id=d6690e2699 href="http://www.ncbi.nlm.nih.gov/pubmed/26593142">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2702 href="https://doi.org/10.1016/j.ccm.2015.08.010">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d6690e2711 class=n-a></a>Tavee J, Culver D: Sarcoidosis and small-fiber neuropathy. <i>Curr Pain Headache Rep.</i> 2011; <b>15</b>(3): 201–6. <a target=xrefwindow id=d6690e2719 href="http://www.ncbi.nlm.nih.gov/pubmed/21298560">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2722 href="https://doi.org/10.1007/s11916-011-0180-8">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d6690e2731 class=n-a></a>De Vries J, Lower EE, Drent M: Quality of life in sarcoidosis: assessment and management. <i>Semin Respir Crit Care Med.</i> 2010; <b>31</b>(4): 485–93. <a target=xrefwindow id=d6690e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/20665398">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2742 href="https://doi.org/10.1055/s-0030-1262216">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d6690e2751 class=n-a></a>Hoitsma E, De Vries J, van Santen-Hoeufft M, <i> et al.</i>: Impact of pain in a Dutch sarcoidosis patient population. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2003; <b>20</b>(1): 33–9. <a target=xrefwindow id=d6690e2762 href="http://www.ncbi.nlm.nih.gov/pubmed/12737278">PubMed Abstract </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d6690e2771 class=n-a></a>Elfferich MD, Nelemans PJ, Ponds RW, <i> et al.</i>: Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. <i>Respiration.</i> 2010; <b>80</b>(3): 212–9. <a target=xrefwindow id=d6690e2782 href="http://www.ncbi.nlm.nih.gov/pubmed/20431280">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2785 href="https://doi.org/10.1159/000314225">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d6690e2794 class=n-a></a>Adams JS, Gacad MA: Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. <i>J Exp Med.</i> 1985; <b>161</b>(4): 755–65. <a target=xrefwindow id=d6690e2802 href="http://www.ncbi.nlm.nih.gov/pubmed/3838552">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2805 href="https://doi.org/10.1084/jem.161.4.755">Publisher Full Text </a> | <a target=xrefwindow id=d6690e2808 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2189055">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d6690e2818 class=n-a></a>Drent M, Wirnsberger RM, de Vries J, <i> et al.</i>: Association of fatigue with an acute phase response in sarcoidosis. <i>Eur Respir J.</i> 1999; <b>13</b>(4): 718–22. <a target=xrefwindow id=d6690e2829 href="http://www.ncbi.nlm.nih.gov/pubmed/10362029">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2832 href="https://doi.org/10.1034/j.1399-3003.1999.13d03.x">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733678174"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2841 class=n-a></a>Aggarwal AN, Sahu KK, Gupta D: Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2016; <b>33</b>(2): 124–9. <a target=xrefwindow id=d6690e2849 href="http://www.ncbi.nlm.nih.gov/pubmed/27537714">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733678174">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d6690e2862 class=n-a></a>Hoitsma E, Faber CG, van Santen-Hoeufft M, <i> et al.</i>: Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2006; <b>23</b>(1): 73–7. <a target=xrefwindow id=d6690e2873 href="http://www.ncbi.nlm.nih.gov/pubmed/16933474">PubMed Abstract </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735359546"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2882 class=n-a></a>Cho PSP, Vasudevan S, Maddocks M, <i> et al.</i>: Physical Inactivity in Pulmonary Sarcoidosis. <i>Lung.</i> 2019; <b>197</b>(3): 285–93. <a target=xrefwindow id=d6690e2893 href="http://www.ncbi.nlm.nih.gov/pubmed/30888492">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2896 href="https://doi.org/10.1007/s00408-019-00215-6">Publisher Full Text </a> | <a target=xrefwindow id=d6690e2900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6520325">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735359546">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732763856"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e2913 class=n-a></a>Lingner H, Buhr-Schinner H, Hummel S, <i> et al.</i>: Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study. <i>Respiration.</i> 2018; <b>95</b>(5): 343–53. <a target=xrefwindow id=d6690e2924 href="http://www.ncbi.nlm.nih.gov/pubmed/29486478">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2927 href="https://doi.org/10.1159/000486964">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732763856">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d6690e2940 class=n-a></a>Panselinas E, Judson MA: Acute pulmonary exacerbations of sarcoidosis. <i>Chest.</i> 2012; <b>142</b>(4): 827–36. <a target=xrefwindow id=d6690e2948 href="http://www.ncbi.nlm.nih.gov/pubmed/23032450">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2951 href="https://doi.org/10.1378/chest.12-1060">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d6690e2961 class=n-a></a>McKinzie BP, Bullington WM, Mazur JE, <i> et al.</i>: Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. <i>Am J Med Sci.</i> 2010; <b>339</b>(1): 1–4. <a target=xrefwindow id=d6690e2972 href="http://www.ncbi.nlm.nih.gov/pubmed/19996733">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2975 href="https://doi.org/10.1097/MAJ.0b013e3181b97635">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d6690e2984 class=n-a></a>Judson MA, Baughman RP, Costabel U, <i> et al.</i>: Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. <i>Eur Respir J.</i> 2014; <b>44</b>(5): 1296–307. <a target=xrefwindow id=d6690e2995 href="http://www.ncbi.nlm.nih.gov/pubmed/25034562">PubMed Abstract </a> | <a target=xrefwindow id=d6690e2998 href="https://doi.org/10.1183/09031936.00000914">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/30413"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3007 class=n-a></a>Baughman RP, Drent M, Kavuru M, <i> et al.</i>: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. <i>Am J Respir Crit Care Med.</i> 2006; <b>174</b>(7): 795–802. <a target=xrefwindow id=d6690e3018 href="http://www.ncbi.nlm.nih.gov/pubmed/16840744">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3021 href="https://doi.org/10.1164/rccm.200603-402OC">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/30413">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d6690e3034 class=n-a></a>Vorselaars AD, Crommelin HA, Deneer VH, <i> et al.</i>: Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. <i>Eur Respir J.</i> 2015; <b>46</b>(1): 175–85. <a target=xrefwindow id=d6690e3045 href="http://www.ncbi.nlm.nih.gov/pubmed/25929955">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3048 href="https://doi.org/10.1183/09031936.00227014">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d6690e3057 class=n-a></a>Gibson GJ, Prescott RJ, Muers MF, <i> et al.</i>: British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. <i>Thorax.</i> 1996; <b>51</b>(3): 238–47. <a target=xrefwindow id=d6690e3068 href="http://www.ncbi.nlm.nih.gov/pubmed/8779124">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3071 href="https://doi.org/10.1136/thx.51.3.238">Publisher Full Text </a> | <a target=xrefwindow id=d6690e3075 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1090632">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d6690e3084 class=n-a></a>Sharma OP: Pulmonary sarcoidosis and corticosteroids. <i>Am Rev Respir Dis.</i> 1993; <b>147</b>(6 Pt 1): 1598–600. <a target=xrefwindow id=d6690e3092 href="http://www.ncbi.nlm.nih.gov/pubmed/8503575">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3095 href="https://doi.org/10.1164/ajrccm/147.6_Pt_1.1598">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d6690e3105 class=n-a></a>Judson MA, Baughman RP, Costabel U, <i> et al.</i>: The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. <i>Respir Med.</i> 2014; <b>108</b>(1): 189–94. <a target=xrefwindow id=d6690e3116 href="http://www.ncbi.nlm.nih.gov/pubmed/24361164">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3119 href="https://doi.org/10.1016/j.rmed.2013.11.019">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d6690e3128 class=n-a></a>Schutt AC, Bullington WM, Judson MA: Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. <i>Respir Med.</i> 2010; <b>104</b>(5): 717–23. <a target=xrefwindow id=d6690e3136 href="http://www.ncbi.nlm.nih.gov/pubmed/20089389">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3139 href="https://doi.org/10.1016/j.rmed.2009.12.009">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718556169"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3148 class=n-a></a>Baughman RP, Winget DB, Lower EE: Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2000; <b>17</b>(1): 60–6. <a target=xrefwindow id=d6690e3156 href="http://www.ncbi.nlm.nih.gov/pubmed/10746262">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718556169">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d6690e3169 class=n-a></a>Lower EE, Baughman RP: Prolonged use of methotrexate for sarcoidosis. <i>Arch Intern Med.</i> 1995; <b>155</b>(8): 846–51. <a target=xrefwindow id=d6690e3177 href="http://www.ncbi.nlm.nih.gov/pubmed/7717793">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3180 href="https://doi.org/10.1001/archinte.1995.00430080088011">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d6690e3189 class=n-a></a>Müller-Quernheim J, Kienast K, Held M, <i> et al.</i>: Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. <i>Eur Respir J.</i> 1999; <b>14</b>(5): 1117–22. <a target=xrefwindow id=d6690e3200 href="http://www.ncbi.nlm.nih.gov/pubmed/10596700">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3203 href="https://doi.org/10.1183/09031936.99.14511179">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718556170"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3212 class=n-a></a>Vorselaars ADM, Wuyts WA, Vorselaars VMM, <i> et al.</i>: Methotrexate vs azathioprine in second-line therapy of sarcoidosis. <i>Chest.</i> 2013; <b>144</b>(3): 805–12. <a target=xrefwindow id=d6690e3223 href="http://www.ncbi.nlm.nih.gov/pubmed/23538719">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3226 href="https://doi.org/10.1378/chest.12-1728">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718556170">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718364824"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3240 class=n-a></a>Sweiss NJ, Noth I, Mirsaeidi M, <i> et al.</i>: Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2014; <b>31</b>(1): 46–54. <a target=xrefwindow id=d6690e3251 href="http://www.ncbi.nlm.nih.gov/pubmed/24751453">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4134103">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718364824">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d6690e3267 class=n-a></a>Baughman RP, Engel PJ, Taylor L, <i> et al.</i>: Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. <i>Chest.</i> 2010; <b>138</b>(5): 1078–85. <a target=xrefwindow id=d6690e3278 href="http://www.ncbi.nlm.nih.gov/pubmed/20348196">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3281 href="https://doi.org/10.1378/chest.09-2002">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733367887"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3290 class=n-a></a>Baughman RP, Shlobin OA, Wells AU, <i> et al.</i>: Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. <i>Respir Med.</i> 2018; <b>139</b>: 72–8. <a target=xrefwindow id=d6690e3301 href="http://www.ncbi.nlm.nih.gov/pubmed/29858005">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3304 href="https://doi.org/10.1016/j.rmed.2018.04.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733367887">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d6690e3317 class=n-a></a>Lewis MM, Mortelliti MP, Yeager H Jr, <i> et al.</i>: Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2002; <b>19</b>(2): 154–9. <a target=xrefwindow id=d6690e3328 href="http://www.ncbi.nlm.nih.gov/pubmed/12102612">PubMed Abstract </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d6690e3337 class=n-a></a>Baughman RP, Lower EE: Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. <i>Respir Med.</i> 2013; <b>107</b>(12): 2009–13. <a target=xrefwindow id=d6690e3345 href="http://www.ncbi.nlm.nih.gov/pubmed/24211131">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3348 href="https://doi.org/10.1016/j.rmed.2013.10.014">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d6690e3357 class=n-a></a>Kravitz JN, Berry MW, Schabel SI, <i> et al.</i>: A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. <i>Chest.</i> 2013; <b>143</b>(5): 1414–21. <a target=xrefwindow id=d6690e3368 href="http://www.ncbi.nlm.nih.gov/pubmed/23117277">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3371 href="https://doi.org/10.1378/chest.12-1784">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d6690e3381 class=n-a></a>Denning DW, Pleuvry A, Cole DC: Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. <i>Eur Respir J.</i> 2013; <b>41</b>(3): 621–6. <a target=xrefwindow id=d6690e3389 href="http://www.ncbi.nlm.nih.gov/pubmed/22743676">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3392 href="https://doi.org/10.1183/09031936.00226911">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d6690e3401 class=n-a></a>Baughman RP, Engel PJ, Nathan S: Pulmonary Hypertension in Sarcoidosis. <i>Clin Chest Med.</i> 2015; <b>36</b>(4): 703–14. <a target=xrefwindow id=d6690e3409 href="http://www.ncbi.nlm.nih.gov/pubmed/26593143">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3412 href="https://doi.org/10.1016/j.ccm.2015.08.011">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d6690e3421 class=n-a></a>Polychronopoulos VS, Prakash UBS: Airway involvement in sarcoidosis. <i>Chest.</i> 2009; <b>136</b>(5): 1371–80. <a target=xrefwindow id=d6690e3429 href="http://www.ncbi.nlm.nih.gov/pubmed/19892676">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3432 href="https://doi.org/10.1378/chest.08-2569">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727722157"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3441 class=n-a></a>Uzunhan Y, Nunes H, Jeny F, <i> et al.</i>: Chronic pulmonary aspergillosis complicating sarcoidosis. <i>Eur Respir J.</i> 2017; <b>49</b>(6): pii: 1602396. <a target=xrefwindow id=d6690e3452 href="http://www.ncbi.nlm.nih.gov/pubmed/28619957">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3455 href="https://doi.org/10.1183/13993003.02396-2016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727722157">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726089410"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3468 class=n-a></a>Taimeh Z, Hertz MI, Shumway S, <i> et al.</i>: Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA. <i>Thorax.</i> 2016; <b>71</b>(4): 378–9. <a target=xrefwindow id=d6690e3479 href="http://www.ncbi.nlm.nih.gov/pubmed/26781176">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3482 href="https://doi.org/10.1136/thoraxjnl-2015-207497">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726089410">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718391827"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3495 class=n-a></a>King TE Jr, Bradford WZ, Castro-Bernardini S, <i> et al.</i>: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. <i>N Engl J Med.</i> 2014; <b>370</b>(22): 2083–92. <a target=xrefwindow id=d6690e3506 href="http://www.ncbi.nlm.nih.gov/pubmed/24836312">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3509 href="https://doi.org/10.1056/NEJMoa1402582">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718391827">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718391829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6690e3523 class=n-a></a>Richeldi L, Du Bois RM, Raghu G, <i> et al.</i>: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. <i>N Engl J Med.</i> 2014; <b>370</b>(22): 2071–82. <a target=xrefwindow id=d6690e3534 href="http://www.ncbi.nlm.nih.gov/pubmed/24836310">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3537 href="https://doi.org/10.1056/NEJMoa1402584">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718391829">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d6690e3550 class=n-a></a>Flaherty KR, Wells AU, Cottin V, <i> et al.</i>: Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. <i>N Engl J Med.</i> 2019; <b>381</b>(18): 1718–1727. <a target=xrefwindow id=d6690e3561 href="http://www.ncbi.nlm.nih.gov/pubmed/31566307">PubMed Abstract </a> | <a target=xrefwindow id=d6690e3564 href="https://doi.org/10.1056/NEJMoa1908681">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2149&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2149&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Pulmonary and Critical Care Medicine, Department of Medicine, Albany Medical College, Albany, NY, USA<br/> <p> <div class=margin-bottom> Marc A Judson <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-2149/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Dec 2019, 8:2149 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.20696.1">https://doi.org/10.12688/f1000research.20696.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Judson MA. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=22762 data-id=20696 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20696.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-2149/v1/pdf?article_uuid=69307855-6eae-4a15-9515-65fd8bdefcdc" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.20696.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Judson MA. Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2149 (<a href="https://doi.org/10.12688/f1000research.20696.1" target=_blank>https://doi.org/10.12688/f1000research.20696.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=20696 id=mobile-track-article-signin-20696 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20696?target=/articles/8-2149"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22762 /> <input name=articleId type=hidden value=20696 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Elliott Crouser</strong>, Division of Pulmonary and Critical Care Medicine, Ohio State University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Leslie Ann Saketkoo</strong>, Scleroderma and Sarcoidosis Patient Care and Research Center, University Medical Center Comprehensive Pulmonary Hypertension Center, Tulane University School of Medicine, USA; Division of Pulmonary Medicine, Louisiana State University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Dominique Valeyre</strong>, Pulmonary Department, Avicenne Universitary Hospital, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2149&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2149&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61452-57713></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61453-57715></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61454-57714></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-2149/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Dec 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Elliott Crouser</strong>, Division of Pulmonary and Critical Care Medicine, Ohio State University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Leslie Ann Saketkoo</strong>, Scleroderma and Sarcoidosis Patient Care and Research Center, University Medical Center Comprehensive Pulmonary Hypertension Center, Tulane University School of Medicine, USA; Division of Pulmonary Medicine, Louisiana State University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Dominique Valeyre</strong>, Pulmonary Department, Avicenne Universitary Hospital, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-2149&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-2149/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Developing better drugs for pulmonary sarcoidosis:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-2149/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-2149/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-2149/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Judson MA');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-2149/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-2149",
            templates : {
                twitter : "Developing better drugs for pulmonary sarcoidosis: determining.... Judson MA, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-2149/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/20696/22762")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "22762");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "57713": 0,
                           "57714": 1,
                           "57715": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "69ae341f-99f4-49a5-935a-f8af971b4fb3";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2149.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2149.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2149.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-2149.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-2149.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>